IP pharma challenges in 2019

In connection to the publication of a new issue of the Stockholm Intellectual Property Law Review, where our researcher Marcus Holgersson serves on the board of directors, a seminar on IP pharma challenges in 2019 was held in Stockholm on June 4, 2019. The seminar covered several important topics, including the use of and uncertainty related to doctrines of equivalents, the opportunities and risks with CRISPR-Cas9 gene editing technologies, and branding and trademarking pharmaceuticals. Much more can be read about these topics in the latest issue of Stockholm Intellectual Property Law Review, available here.

The seminar was followed by a dinner, celebrating the recent graduates of the IP Law master program of Stockholm University. We wish the students best of luck with their future careers in the IP Law field.


Thomas Hedner from IMIT giving a thought-provoking talk on the opportunities and risks with CRISPR-Cas9
Kristina Björnerstedt from Skriptor Zigila talking about the structured process of naming your business, product, or pharmaceutical

John Hornby from Lambert Hornby Ltd talking about the doctrine of equivalents from a UK perspective

Bengt Domeij from Uppsala University giving a Swedish perspective, also on the doctrine of equivalents
Students celebrated by parts of the Swedish IP community